Truist Financial Corp Prometheus Biosciences, Inc. Transaction History

Truist Financial Corp

  • $62.9 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 05, 2023
SELL
$103.46 - $126.29 $177,020 - $216,082
-1,711 Reduced 43.33%
2,238 $240,000
Q4 2022

Feb 17, 2023
BUY
$36.06 - $117.21 $15,289 - $49,697
424 Added 12.03%
3,949 $434,000
Q3 2022

Oct 26, 2022
BUY
$28.17 - $59.01 $99,299 - $208,010
3,525 New
3,525 $208,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email